Cargando…
Determinants of survival outcomes among esophageal cancer patients at a national referral hospital in Kenya
INTRODUCTION: The overall 5‐year survival rate for esophageal cancer patients in low‐ and middle‐income countries was reported to be low, despite the availability of advanced treatments. Thus, this study aimed to assess determinants of survival outcomes among esophageal cancer patients in Kenya. MET...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10011667/ https://www.ncbi.nlm.nih.gov/pubmed/36926251 http://dx.doi.org/10.1002/cdt3.52 |
Sumario: | INTRODUCTION: The overall 5‐year survival rate for esophageal cancer patients in low‐ and middle‐income countries was reported to be low, despite the availability of advanced treatments. Thus, this study aimed to assess determinants of survival outcomes among esophageal cancer patients in Kenya. METHODS: A retrospective cohort study was employed among 299 adult esophageal cancer patients. The data were collected using a data abstraction tool consisting of patients’ clinical characteristics and survival outcome measuring parameters. Statistical Package for the Social Sciences (SPSS) statistical software (version 20.0, IBM. USA) was used to analyze the data. The Kaplan–Meier and Cox regression analyses were used to determine the survival outcome and determinants of mortality, respectively. RESULTS: The mortality rate was 43.1%, and 11.1% of patients demonstrated distant metastases in the follow‐up period. Despite treatment, 20.1% had progressed disease, and 13.0% did not respond to treatment. Radiotherapy (AHR: 3.3, 95% CI: 1.4−7.8, p = 0.007), chemotherapy (AHR: 3.9, 95% CI: 1.2−6.1, p = 0.020), and chemoradiation (AHR: 5.6, 95%CI: 1.6−10.2, p = 0.006) were the significant determinants of survival in advanced stage (III and and IV) patients. CONCLUSIONS: There was a high mortality rate, disease progression, and nonresponse of esophageal cancer patients. Hence, it is essential to improve the survival of patients through early detection and timely initiation of the available treatment options. |
---|